ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

0Q6H Hofseth Biocare Asa

2.00
0.00 (0.00%)
18 Jul 2025 - Closed
Share Name Share Symbol Market Type Share ISIN Share Description
Hofseth Biocare Asa LSE:0Q6H London Ordinary Share NO0010598683 HOFSETH BIOCARE ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 265.54M -125.3M -0.3048 -6.56 822.16M

Hofseth Biocare ASA: HBC ANNUAL REPORT 2024

11/04/2025 12:45pm

UK Regulatory


Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart


From Jan 2025 to Jul 2025

Click Here for more Hofseth Biocare Asa Charts.
Hofseth Biocare ASA: HBC ANNUAL REPORT 2024

The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2024, and HBC has today published the Annual Report and Sustainability Report for 2024.

Please find the Annual Report and ESG Report attached.

For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA:
Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry by taking fresh filleted salmon and converting it from a waste product into ingredients to improve human and pet health. These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®, a whole salmon oil, with all the fatty acid fractions contained in fish, and CalGo® / NT-II(TM) salmon bone powder containing calcium hydroxyapatite and undenatured collagen for bone and joint health. HBC places scientific evidence at the forefront which has led to important academic partnerships and the identification of unique health benefits. This includes the demonstration of improved iron metabolism by boosting the body's ability to take up and use iron resulting in increased energy and vitality with ProGo® as well as the activation of the GLP-1 receptor with fat reduction in overweight adults.

OmeGo® has shown important immune health benefits including recovery from viral infection and improved respiratory health and sleep in adults troubled by particulate matter pollution. Finally, CalGo® has shown both bone and joint health benefits to support healthy ageing and active lifestyles. This work has also resulted in the granting of several patents protecting these discoveries. It has also led to the discovery of potential therapeutics and HBC has spun out a biotech-focused company, HBC Immunology (HBCI). HBCI has raised external finance, and the lead program is in prostate cancer followed by ovarian cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for asthma.

This information is subject to disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments

  • ESG report HBC 2024
  • Hofseth BioCare 2024 Annual report en
  • hofsethbiocareasa-2024-12-31-0-en

1 Year Hofseth Biocare Asa Chart

1 Year Hofseth Biocare Asa Chart

1 Month Hofseth Biocare Asa Chart

1 Month Hofseth Biocare Asa Chart

Your Recent History

Delayed Upgrade Clock